US 11,439,683 B2 · Anti-angiogenic therapy of metastatic colorectal cancer

Abstract

The present invention provides methods for treating metastatic cancer comprising identifying subjects who will respond favorably to anti-VEGF therapy. According to certain aspects of the invention, subjects are identified based on their expression level of one or more predictive biomarkers. Favorable response to anti-VEGF therapy is indicated by high expression levels of certain biomarkers or by low expression levels of certain biomarkers. An exemplary predictive biomarker is VEGF-A. Also disclosed herein are prognostic biomarkers useful for identifying cancer-bearing subjects who are expected to have better relative survival outcomes.

Claims8

Dependent claims

A method for treating metastatic colorectal cancer (mCRC) in a patient comprising administering a VEGF Trap that comprises Ig-like domain 2 of VEGFR1, Ig-like domain 3 of VEGFR2, and a multimerizing domain, to the patient,

wherein the patient has been identified as likely to respond favorably to VEGF Trap therapy by a method comprising obtaining a sample from the patient and measuring in the sample the level of VEGF-A;
wherein an elevated level of expression of VEGF-A identifies the patient as a patient who is likely to respond favorably to VEGF Trap therapy, and
wherein the elevated expression of VEGF-A is determined based on a comparison to the lower level of VEGF-A in subjects with mCRC.

Dependencies are inferred from the claim text.

Facts

Application

16/690,459Filed 21 Nov 2019 · division

Priority

16 Sep 2014

Published

US 2020/0129589 A130 Apr 2020

Granted

13 Sep 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification11 codes

A61K 38/179
Receptors; Cell surface antigens; Cell surface determinants: for growth factors; for growth regulators
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 35/00
Antineoplastic agents
A61P 35/04
Antineoplastic agents: specific for metastasis

Family

Application62/051,091Us provisional application · filed 16 Sep 2014

Application62/099,630Us provisional application · filed 5 Jan 2015

PCT/US2015/049279Parent of this division · filed 10 Sep 2015

US 2020/0129589 A1Pre-grant publication · published 30 Apr 2020

Application15/509,461Parent of this division

US 10,525,104 B2Parent of this division

US 2017/0281725 A1Published application

US 11,439,683 B2This patent

From the US filing history. Foreign family members aren’t listed.

Anti-angiogenic therapy of metastatic colorectal cancer

Life of this patent

Anti-angiogenic therapy of metastatic colorectal cancer

Life of this patent

Abstract

Claims8